Patients with HER2-positive metastatic breast cancer who have previously been treated with trastuzumab and a taxane are potential candidates for T-DM1. Before starting treatment, patients should undergo tests to confirm HER2 positivity and be evaluated for any existing health conditions that might affect treatment.
